|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
43,700,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Prelude Therapeutics is a clinical-stage oncology company built on a foundation of drug discovery to deliver precision cancer medicines to underserved patients. Co.'s primary candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5 (PRMT5). PRT811, Co.'s second clinical candidate, is a PRMT5 inhibitor that it has optimized for high brain exposure. PRT1419, Co.'s third clinical candidate, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527, Co.'s fourth clinical candidate, is designed to be a potent and selective Cyclin-dependent kinase 9 inhibitor.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,760,286 |
1,799,474 |
Total Buy Value |
$0 |
$0 |
$10,116,973 |
$10,305,319 |
Total People Bought |
0 |
0 |
5 |
5 |
Total Buy Transactions |
0 |
0 |
7 |
10 |
Total Shares Sold |
0 |
0 |
0 |
13,280 |
Total Sell Value |
$0 |
$0 |
$0 |
$81,274 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Piper Brian |
Chief Financial Officer |
|
2021-05-25 |
4 |
OE |
$1.89 |
$15,749 |
D/D |
8,333 |
8,333 |
|
- |
|
Scherle Peggy |
Chief Scientific Officer |
|
2021-05-07 |
4 |
AS |
$40.30 |
$408,192 |
D/D |
(10,000) |
172,920 |
|
- |
|
Scherle Peggy |
Chief Scientific Officer |
|
2021-05-07 |
4 |
OE |
$1.43 |
$14,300 |
D/D |
10,000 |
182,920 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-05-05 |
4 |
AS |
$39.36 |
$602,092 |
D/D |
(15,000) |
0 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-05-05 |
4 |
OE |
$1.89 |
$28,350 |
D/D |
15,000 |
15,000 |
|
- |
|
Morosini Deborah |
EVP, Chief of Clinical Affairs |
|
2021-04-29 |
4 |
AS |
$40.29 |
$129,853 |
D/D |
(3,223) |
444 |
|
- |
|
Morosini Deborah |
EVP, Chief of Clinical Affairs |
|
2021-04-29 |
4 |
OE |
$1.89 |
$6,091 |
D/D |
3,223 |
3,667 |
|
- |
|
Pierce Christopher |
EVP and Chief of Business Oper |
|
2021-04-29 |
4 |
AS |
$40.29 |
$132,765 |
D/D |
(3,295) |
3,750 |
|
- |
|
Pierce Christopher |
EVP and Chief of Business Oper |
|
2021-04-29 |
4 |
OE |
$1.89 |
$6,228 |
D/D |
3,295 |
7,045 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-04-27 |
4 |
AS |
$34.66 |
$884,848 |
D/D |
(25,000) |
0 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-04-27 |
4 |
OE |
$1.89 |
$47,250 |
D/D |
25,000 |
25,000 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-04-19 |
4 |
AS |
$30.82 |
$772,349 |
D/D |
(25,000) |
0 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-04-19 |
4 |
OE |
$1.89 |
$47,250 |
D/D |
25,000 |
25,000 |
|
- |
|
Pierce Christopher |
EVP and Chief of Business Oper |
|
2021-04-08 |
4 |
AS |
$40.00 |
$8,000 |
D/D |
(200) |
3,750 |
|
- |
|
Pierce Christopher |
EVP and Chief of Business Oper |
|
2021-04-08 |
4 |
A |
$1.89 |
$378 |
D/D |
200 |
3,950 |
|
- |
|
Scherle Peggy |
Chief Scientific Officer |
|
2021-04-08 |
4 |
AS |
$36.97 |
$177,504 |
D/D |
(4,630) |
172,920 |
|
- |
|
Scherle Peggy |
Chief Scientific Officer |
|
2021-04-08 |
4 |
A |
$1.43 |
$6,621 |
D/D |
4,630 |
177,550 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-04-08 |
4 |
AS |
$37.04 |
$368,852 |
D/D |
(9,617) |
0 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-04-08 |
4 |
OE |
$1.89 |
$18,176 |
D/D |
9,617 |
9,617 |
|
- |
|
Morosini Deborah |
EVP, Chief of Clinical Affairs |
|
2021-04-08 |
4 |
AS |
$40.00 |
$4,000 |
D/D |
(100) |
444 |
|
- |
|
Morosini Deborah |
EVP, Chief of Clinical Affairs |
|
2021-04-08 |
4 |
OE |
$1.89 |
$189 |
D/D |
100 |
544 |
|
- |
|
Pierce Christopher |
EVP and Chief of Business Oper |
|
2021-04-07 |
4 |
AS |
$40.08 |
$33,188 |
D/D |
(828) |
3,750 |
|
- |
|
Pierce Christopher |
EVP and Chief of Business Oper |
|
2021-04-07 |
4 |
A |
$1.89 |
$1,565 |
D/D |
828 |
4,578 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-04-07 |
4 |
AS |
$39.03 |
$605,023 |
D/D |
(15,383) |
0 |
|
- |
|
Mauro David J |
Chief Medical Officer |
|
2021-04-07 |
4 |
OE |
$1.89 |
$29,074 |
D/D |
15,383 |
15,383 |
|
- |
|
100 Records found
|
|
Page 3 of 4 |
|
|